It’s been more than three years since DBV Technologies’ peanuty allergy therapy was rejected for FDA approval, but the company thinks it now has a clear route to market with its patch product ...
Abrupt cuts by the Trump administration to the US National Institutes of Health threaten progress in medical research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback